NEW YORK (GenomeWeb) – A Thermo Fisher Scientific spokesman today confirmed the company’s acquisition of Linkage Biosciences for an undisclosed amount.
Following the transaction, completed on Monday, Linkage is now part of Thermo Fisher’s transplant diagnostics business, One Lambda. Based in South San Francisco, California, Linkage develops and markets molecular diagnostic technologies for complex genetic testing. Its flagship product line is LinkSeq, a real-time PCR genotyping technology. Linkage provides HLA-typing kits, KIR-typing kits, HPA-typing kits, instruments such as liquid handler kit instruments, and accessories, according to the firm’s website.
In a July 11 letter to customers, Parisa Khosropour, president of Thermo Fisher’s transplant diagnostic business, said that with the acquisition, that business now serves more than 1,000 transplant centers across more than 60 countries.
Benefits stemming from the acquisition include a broader and deeper range of products, a continued commitment to innovation, and expanded support globally, the letter said.
Zachary Antovich was president and CEO of Linkage. It is unclear if he is remaining with the firm.